| Articolul precedent |
| Articolul urmator |
 |
 334 5 |
| Ultima descărcare din IBN: 2024-02-15 22:42 |
 SM ISO690:2012GOLUB, Aliona. Tratamentul paciențillor cu recăderi ale limfomului Hodgkin. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 225. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
|
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
| Pag. 225-225 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Background. Hodgkin's lymphoma (LH) is a malignant tumor that develops in the lymphatic tissue. Although the treatment effectiveness and the healing potential are high, in some patients with local stages, there are up to 10-15% of relapses, which negatively influence the prognosis. Objective of the study. To study the results of relapse treatment in patients with stages I and II of HL. Material and Methods. The results of the treatment of relapses that developed in 78 patients, aged 18 to 78 years, with HL, initially diagnosed with stages I and II, with complete remissions due to the first-line therapy, were studied. The treatment was performed with 6-8 cycles of polychemotherapy (PChT): ABVD - in 33 patients, CVPP - in 38, BEACOPP - in 7 Results. The treatment efficacy was higher in patients in whom PChT BEACOPP was used; complete remission (CR) constituted 85.7%. In the cases of administration of PChT ABVD, CR accounted for 66.7%, and after PChT CVPP, CR was found only in 31.7% of cases. Progression-free survival (PFS) over 3 years was also higher in cases of PChT BEACOPP administration, and was constituted 100%, as opposed to PFS in the same terms, when applying PChT ABVD and CVPP, which amounted to 81.3 % and 73.7%, respectively. Conclusion. The BEACOPP regimen constituted the optimal treatment regimen for HL relapses. |
||||||
| Cuvinte-cheie Hodgkin's lymphoma, relapses, treatment, limfom Hodgkin, recăderi, Tratament |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Golub, A.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='ro,en'>Tratamentul paciențillor cu recăderi ale limfomului Hodgkin</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2020</publicationYear> <relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'></relatedIdentifier> <subjects> <subject>Hodgkin's lymphoma</subject> <subject>relapses</subject> <subject>treatment</subject> <subject>limfom Hodgkin</subject> <subject>recăderi</subject> <subject>Tratament</subject> </subjects> <dates> <date dateType='Issued'>2020</date> </dates> <resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Background. Hodgkin's lymphoma (LH) is a malignant tumor that develops in the lymphatic tissue. Although the treatment effectiveness and the healing potential are high, in some patients with local stages, there are up to 10-15% of relapses, which negatively influence the prognosis. Objective of the study. To study the results of relapse treatment in patients with stages I and II of HL. Material and Methods. The results of the treatment of relapses that developed in 78 patients, aged 18 to 78 years, with HL, initially diagnosed with stages I and II, with complete remissions due to the first-line therapy, were studied. The treatment was performed with 6-8 cycles of polychemotherapy (PChT): ABVD - in 33 patients, CVPP - in 38, BEACOPP - in 7 Results. The treatment efficacy was higher in patients in whom PChT BEACOPP was used; complete remission (CR) constituted 85.7%. In the cases of administration of PChT ABVD, CR accounted for 66.7%, and after PChT CVPP, CR was found only in 31.7% of cases. Progression-free survival (PFS) over 3 years was also higher in cases of PChT BEACOPP administration, and was constituted 100%, as opposed to PFS in the same terms, when applying PChT ABVD and CVPP, which amounted to 81.3 % and 73.7%, respectively. Conclusion. The BEACOPP regimen constituted the optimal treatment regimen for HL relapses.</p></description> <description xml:lang='ro' descriptionType='Abstract'><p>Introducere. Limfomul Hodgkin (LH) este o tumoră malignă care se dezvoltă din țesutul limfatic. Deși eficacitatea tratamentului este înaltă și potențialul de vindecare este mare la o parte dintre pacienți în stadiile locale până la 10-15%, la o etapă oarecare apar recăderi. Scopul lucrării. Studierea rezultatelor tratamentului recăderilor la pacienții cu stadiile I și II ale LH. Material și Metode. Au fost studiate rezultatele tratamentului recăderilor care s-au dezvoltat la 78 de pacienți cu LH, diagnosticați inițial în stadiile I și II cu remisiuni complete, obținute pe fondalul terapiei de primă linie, cu vârsta de la 18 până la 78 de ani. Tratamentul a fost efectuat cu 6-8 cicluri de polichimioterapie (PChT): ABVD la 33 de pacienți, CVPP – la 38, BEACOPP - la 7. Rezultate. Eficacitatea tratamentului a fost mai înaltă la pacienții la care s-au utilizat PChT BEACOPP, remisiunile complete (RC) au constituit 85,7%. În cazurile de administrare a PChT ABVD RC au fost obținute la 66,7% pacienți, iar la efectuarea PChT CVPP RC au fost constatate doar în 31,7% cazuri. Supraviețuirea fără progresie (SFP) peste 3 ani, de asemenea, a fost mai înaltă în cazurile de administrare a PChT BEACOPP și a fost egală cu 100% spre deosebire de SFP în aceiași termeni la aplicarea PChT ABVD și CVPP care a constituit 81,3% și 73,7%, respectiv. Concluzii. Schema optimală de tratament a recăderilor LH a fost schema BEACOPP.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>
|
|
|
